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SUMMARY PAGE
THE PROBLEM
Carrier flight operations often involve repeated, extended missions that are separated by short
periods of rest. When these factors combine with high cockpit workload and the stress of combat, aircrew
performance may become impaired. Several countermeasures, including the use of pharmacological
intervention, have been proposed to alleviate the detrimental effects of sustained flight operations (SUSOPs).
For example, one solution is to introduce a short-acting stimulant that could alleviate the impact of SUSOPs,
delay performance decrement, and reduce subjective feelings of fatigue with minimal central nervous system
(CNS) side effects. Amphetamines, have shown promise in counteracting some of the performance
decrements and subjective fatigue associated with SUSOPs, but more research is needed.
FINDINGS
Following a simulated SUSOP scenario where subjects were administered either 10 mg of d-
methamphetamine/70 kg of body mass, or a placebo, differences in fatigue and sleepiness were found
between the methamphetamine and placebo groups. Results indicated that the administration of 10 mg of d-
methamphetamine/70 kg of body mass significantly decreased subjective feelings of fatigue.
CONCLUSIONS
The amphetamines have been shown to abate subjective fatigue and improve degraded performance,
however, this may not be sufficient evidence to recommend their use at this time. Several important
operational considerations need to be addressed before recommendations could be proposed to the fleet.
These issues include, but are not limited to:
1. Whether stimulants are the best solution to the SUSOPs problem?
2. Which stimulant is the best choice for use during SUSOPs?
3. What is the effect of the drug on flight performance?
4. What is the most efficacious dose, and how frequently could this be safely repeated
during a mission?
5. When is the optimum time to use the drug during a mission?
6. What is the effect of the drug on sleep latency and how will this impact subsequent
crew rest following its use during a mission?
7. What constitutes a practical and effective screening program?
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INTRODUCTION
Naval aircrews frequently fly multiple extended missions separated by brief periods of crew rest.
As such, sustained flight operations (SUSOPs) can have a disruptive effect on routine. sleep patterns. These
disruptions often take the form of partial sleep loss, disruption of sleep-wakefulness cycles, and circadian
desynchronosis. Any one or more of these factors may combine with high-workload schedules to impair
aircrew performance (1).
Several countermeasures have been proposed to alleviate the detrimental effects of SUSOPs on
aircrews (2). Some that have been proposed include adequate squadron staffing, cross-training aircrews to
enable one crew member to relieve another, and work/rest scheduling which reflects disruptions of circadian
rhythm (3). Other less obvious countermeasures that may be considered include physical fitness and exercise
(4), nutrition (5), and sleep strategies (6). In addition, pharmacological intervention may hold some promise.
Two classes of pharmacological cuuntermeasures have received attention: hypnotics and stimulants.
Hypnotics could increase the quality of sleep when the opportunity for sleep arises (7). The optimal hypnotic
agent would decrease sleep latency, preserve normal sleep architecture, and exhibit no residual effects.
Recent attention b ? focused on the use of benzodimzepines. Although clinically tested, more applied
research is needed 'warrant their use in the fleet.
Stimulants have been effective in countering the effects of SUSOPs (8,9). For example, caffeine
enhances performance (10,11) and alleviates the effects of sleep loss (12) although the duration and
magnitude of its effects are less than other stimulants (13). Other disadvantages of caffeine at doses likely to
be useful in counteracting fatigue (> 200 mg) include tolerance, anxiety, tremor, and dysphoria (11,14).
Several other stimulants such as magnesium pemoline, methylphenidate, ephedrine, phenmetrazine, pipradol,
and phezldamine have demonstrable effects on performance as well (15,16). They also possess undesirable
side effects, however, that limit their use by aircrews (10,16).
We desired a short acting stimulant with minimal central nervous system (CNS) side effects that was
known to delay performance decrements and counteract mood changes related to SUSOPs. The
amphetamines, particularly d-amphetamine, have been successful in counteracting some performance
decrements and mood changes associated with SUSOPs (8,9,17). Weiner (18) found that methamphetamine
demonstrated greater CNS potency with less peripheral cardiovascular side effects than racemic
amphetamine, while Martin et al. (16) found no differences in physiological, subjective, or behavioral effects
between d-amphetamine and d-methamphetamine. Brown et al. (19) found the elimination half-life for
d-amphetamine to be approximately 6-7 h, while the biological half-life for methamphetamine has been
reported in the range of 4-5 h (20). Given these considerations, we chose to conduct our study usingd-methamphotamine.
Aircrews who continually perceive themselves as highly fatigued may eventually show a loss in
morale, which adversely affects operational effectiveness. Therefore, an important part of this research has
been to evaluate subjective fatigue during SUSOPs. Although several questionnaires effectively measure
subjective fatigue and sleepiness, not all of them can differentiate between drug and placebo effects. As a
result, we selected instruments from three specialty areas: the Addiction Research Center Inventory (ARCI)
from the pharmacological literature (21) the Mood Questionnaire (MQ) from the psychiatric literature (22),
and the Stanford Sleepiness Scale (SSS) from the sleep literature (23,24).
METHODS
SUBJECTS
Twenty-five male U.S. Marines, 22-28 years old, volunteered for the study. Subjects were awaiting
assignment to primary flight training. All subjects were commissioned officers who had completed a college
dogvee program. Before participation, each subject passetd a fright physical and was screened for drug use.
APPARATUS
Tests were presented using Zenith Z-248 microcomputers equipped as described in a related paper
(25). The six work stations were linked by a Local Area Network (LAN) to ensure the simultaneous presen-
tation of the tasks.
TRAINING
Subjects trained for 6 days beginning on a Monday. The final training session was conducted on the
following Monday to counteract any loss of training over the weekend. Subjects completed 5 administrations
of the ARCY, and 10 administrations of the MQ and SSS for familiarization before the experiment.
EXPERIMENTAL DESIGN
The experimental design is shown in Fig. 1. As in a similar study (25) the simulated SUSOP
consisted of 9 h of preflight planning (Planning I), 4 h of rest, and a 14-h mission (Mission I). To simulate
cyclical operations, two iterations of the preceding schedule were incorporated in the experiment, separated
by a 6-h rest period. The planning and mission segments during the second cycle are labeled Planning II and
Mission II in Fig. 1. Subjects were continuously monitored to ensure that they did not fall asteep during the
study. Four hours and 20 win into the second mission (50 h and 40 min from the onset of the SUSOP), 13
subjects were administered 10 mg of d-methamphetamine hydrochloride/70 kg of body mass (Arenol
Chemical Corp.) while 12 subjects received a placebo (lactose), following a double-blind procedure. Both
the placebo and d-methamphetamine were administered in No. .0 gelatin capsules (Eli Lilly & Co.). Lactose
powder was added to the appropriate dose of d-methamphetamine to fill the capsules.
The testing environment was strictly controlled. Social interaction was limited to the minimum
necessary to conduct the study. The windows in the testing room were covered, and no watches or docks
were permitted in the testing areas to reduce thide-of-day cues. Dietary intake was limited to 3100 cal per
day. Nicotine products were prohibited as well as beverages containing methyl-xanthenes.
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Figure 1. Schedule for simislated suvtained flight operations (SUSOPs) scenario.
Each symbol represents a separate test administration. Pill administration
(not shown) occurred at 2040 on day 3 (50 h 40 rain elapsed time).
MEASURES
The ARCI, SSS, and MO were part of a group of subjective, cognitive and physiological measures
used during a the study. Although the ARCI and MQ ate each comprised of several scales, each contains a
fatigue scale. We restricted cur analysis to the fatigue scales because we were primarily interested in fatigue
during SUSOPs. A computerized flight simulator was used to occupy the subjects' time between sessions 8
and 9 during Mission I, and sessions 17 and 18 during Mission II. A generic performance assessment battery
(G-PAB) was periodically administered to measure cognitive performance. The cognitive test results are
reported separately (25,26). In addition, several physiological measurements, including heart rate, blood
pressure, grip strength, electrocardiogram, electroencephalogram and urine output were collected for future
analysis. All subjective questionna~os and cognitive tasks were computerized and presented to the subjects
on a CRT screen for ease of administration. Responses for the ARCI and the flight simulator were made
using a standard computer keyboard, while responses for the MO and SSS were made using the Mini-
Modulus III keypad.
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Addiction Research Center Inventory (ARCI)
The ARCI used in this study was a subset of the one originally developed by Heartzen (21) and later
expanded by Martin et al. (16). The ARCI was designed specifically to 1) distinguish between drug and
placebo conditions, 2) determine dose-effect relationships, and 3) distinguish between different drugs. We
used 5 of the 10 original scales: PCAG (pentobarbital, cllorpromazine, and alcohol group), MBG
(morphine-amphetamine group), LSD (lysergic acid diethylamide), A (amphetamine), and BG (amphetamine
group). The PCAG scale is a measure of fatigue, the MBG scale represents euphoria, the LSD scale is an
indication of depersonalization, and the A and BG scales are both measurements of intellectual efficiency.
The scales that were not included apply to pharmacological agents other than amphetamine. What makes
the ARCI particularly appealing is its successful use in the investigation of subjective and behavioral effects
of amphetamines (16,27).
During each trial, a statement was displayed to the subject. Subjects were instructed to answer
"true" if the statement applied to them at that time and "false" if it did not. A total of 47 statements from
the 5 selected scales were combined and displayed randomly during each session. Fifteen of the 47
statements presented during each session were associated with the fatigue scale (see Appendix A for ARCI
fatigue scale statements). Scores could range from 0 (no fatigue) to 15 (maximum fatigue).
Stanford Sleepiness Scale (SSS)
The SSS is a self-rating scale used to quantify progressive steps in sleepiness developed by Hoddes et
al. (23,24) in an effort to correlate subjective sleepiness ratings with performance. During each session,
seven items were simultaneo~Asly presented to the subjects. Subjects were instructed to cnter the scale value
of the statement that best described their statc. of sleepiness (see Appendix B for the SSS statements and
their scale values). Scale valves could range from 1 (wide awake and alert) to 7 (ready to fall asleep).
Mood Questionnaire (MQ).
The MQ was developed by Ryman et al. (22) Ls an abbreviated test to measu -, the moods and
emotions of individuals in a form that was more amenable to field research. The questionnaire, which
consists of six scales including happiness, activity, depression, fear, anger, and fatigue, has been validated
using several objective performance criteria (28-30).
During each trial, an adjective was preeanted to the subject. Subjects were instructed to indicate
how each word applied to them by using a three-choice response format (1 = not at all, 2 = somewhat or
slightly, 3 = mostly or generally). During each session, 36 adjectives from the 6 scales were randomly
displayed. Five of the 36 adjectives comprised the Fatigue scale (see Appendix C for MO fatigue scale
adjectives). Scores could range from 5 (no fatigue) to 15 (generally fatigued).
The SSS and MO were administered 18 times during tbe testing period as part of a larger study, as
illustrated in Fig. 1. There were four administrations during each pianniLg session and five during each
mission session. The ARCI was administered 10 times during the testing period. There were five
administrations during each mission segment, with no administrations during the planning segments.
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RESULTS
We found no differences in reported fatigue/sleepiness between the methamphetamine and placebo
groups before pill administration for any of the questionnaires. Dfferences in fatigue and sleepiness between
the methamphetamine and placebo groups for each administration during Mission II were examined usingplanned comparisons in a group-by-repeated measures design. A significance level ofp < .05 was auopted
for all comparisons. All three subjective inventories showed significantly less fatigue in the drug group
following the administration of methamphetamine.
The methamphetamine group reported significantly less fatigue than the placebo group on the ARCI
at 1 h, F(1, 23) = 11.63 ,17 < .01; 2 h 55 rin, F(1, 23) f 4.25, p < .05; and 4 h 50 min, F(1, 23) = 431, p <
.05, following pill administration (2140 and 2335 on day 3, and 0130 on day 4), as illustrated in Fig 2. At 8 h
20 min post pill (0500 on day 4), reported fatigue was not different between the two groups.
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Figure 2. Subjective fatigue as a function of time for the Addiction Research
Center Inventory (ARCI). Fatigue scores could range from 0 (no fatigue) to 15
(maximum fatigue). (See Appendix A for ARCI fatigue scale statements).
Mean sleepiness scores ranged from 2 ("functioning at a high level") to 3.5 (between "not at full
alertness" and "a little foggy") as illustrated in Fig. 3. There were no differences in reported sleepiness
between the drug and placebo groups 1 h before pill administration and 55 min after pill administration
5
(1940 and 2135 on day 3). At 2 h 50 min post pill (2330 on day 3), the methamphetamine group reported
less sleepiness than the placebo group, F(1, 23) = 3.99, p < .05. At that time, the mean scores were 2
("functioning at a high level") for the methamphetamine group and 2.75 (between "able to concentrate but
not at peak" and "not fully alert") for the placebo group. For the remainder of the study, at 4 h 45 min and 8
h 15 min pcft pill (0125 and 0455 on day 4), reported sleepiness was essentially the same for the two groups.
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Figure 3. Subjective fatigue as a function of time for the Stanford
Sleepiness Scale (SSS). Scorn~s could range from 1 (wide awake
and alert) to 7 (ready to fall asleep). (See Appendix B for SSS
statements and their scale values).
The mean subjective fatigue scores for the MO were between 6.7 and 9 (Fig. 4). There were no
differences in reported fatigue between the drug and placebo groups 1 h prior to pill administration, 50 min
post pill administration, and 2 h 50 min post pill administration (1940, 2135, and 2330 on day 3). At 4 h 45
main and 8 h 15 min post pill (0125 and 0455 on day 4), the methamphetamine group reported less fatigue
than the placebo group, F(1, 23) =4.49 and 4.26, respectively, p < .05. During this period, the level of
fatigue reported by both groups appeared to increase.
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Figure 4. Schedule for simulated sustained flight operations (SUSOPs) scenario.
Scores could range from 5 (no fatigue) to 15 (generally fatigued).
(See Appendix C for MQ fatigue scale adjectives).
DISCUSSION
Methamphetamine administration significantly affected the results obtained from the subjective
questionnaires. Fatigue tended to decrease during the simulated SUSOP with the administration of 10 mg of
methamphetamine/70 kg of body mass although the reported fatigue was low for all of the questionnaires.
Consistent with other findings (13,31,32) significant differences in apparent fatigue and sleepiness were found
between the treatment and placebo groups following pill administration.
Fatigue reported by the drug group increased at 0130 and 0430 for the ARCI and the SSS (Figs. 2
and 3, respectively). This may have been a time-of-day effect. Endogenous circadian rhythms have been
established for many physiological, biochemical, and psychological functions. Performance en many tasks
rises to a peak between 1200 and 2100 and falls to a minimum between 0200 and 0600 (1). The increase in
reported fatigue between 0130 and 0430 falls roughly within the 0200-06(x0 circadian trough. Our results are
consistent with the findings of Angus and Heslegrave (33) in which performance between 0200 and 0600
declined from 10 to 15% in non-sleep-deprived individuals to as much as 35 to 40% in sleep-deprived
subjects. These performance decrements were accompanied by a declines in mood, motivation, and initiative.
Other researchers (34,35) have found similar lulls in mood and performance during these times as well.
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Figure 3 suggests that reported sleepiness increased during this period (between 0130 and 0430), indicating
that the subjects may have felt sleepy as well as fatigued.
At times closer to pill administration (1 h 00 min, 2 h 55 min, and 4 h 50 mrin), the ARCI seemed to
detect differences between the methampletamine and placebo subjects better than the MO. Later (8 h 15
mrin), the MQ appeared to be a better measure of subjective fatigue. The methamphetawine group reported
lest fatigue than the placebo group on the final administration of the MO. This was not the case for the
ARCI data. Although we cannot entirely explain the differences between the scales at the final
administration time, they may be due to the metabolism of methamphetamine to amphetamine that is known
to occur (36). It has been proposed that this active metabolite might result in the prolonged effect of
methamphetamine on cognitive performance (26). It is equally possible that the metabolism of
methamphetamine to amphetamine has a similar prolonged effect on subjective fatigue that the ARCI and
SSS were unable to detect. Our data thus demonstrate the need to use caution when selecting subjective
fatigue scales. This study suggests that the ARCI was the most effective at discriminating fatigue while the
SSS was the least discriminative. When information is not available on which particular scale will be the
most useful in a study, we recommend using more than one scale until sufficient data are obtained to make a
decision.
Two factors might have enhanced the effect of methamphetamine on subjective fatigue. First, a
higher dose of methamphetamine might have produced a greater effect. The parent compound, d-
amphetamine, has been shown to ameliorate fatigue in a dose-response fashion (8). The dose of
methamphetamine used in this study was low compared to the dose used in other studies, For example,dosages of d-amphetamine as high as 35 rag/70 kg of body mass have been used to study drug-induced
physiological and behavioral changes in man (37). In addition, clinical doses of methamphetamine of up to
30 mg per day are common for the treatment of hyperactivity in children and obesity in adults (18). A
second factor that might enhance the effect of methamphetamine involves the fatigue level of the subjects.
Subjects in this study may have experienced only mild fatigue following the 60-h partial sleep-deprivation
schedule. Other studies have used total, rather than partial, sleep-deprivation paradigms, and longer sleep-
deprivatia periods ranging from 60 h (8) to 98 h (38). Reported fatigue levels in our study were only
moderate, allowing less of a chance for methamphetamine to reduce subjective fatigue. It is possible that the
effect of methamphetamine might have been greater if the subjects had been more fatigued. Future research
should be directed toward testing higher doses of methamphetamine under conditions of greater fatigue to
allow for a full range of effects.
In this paper, we used subjective scales to evaluate the effect of d-methamphetamine on subjective
fatigue. In a previous paper (26) we used cognitive tasks to investigate the effect of d-methamphetamine on
performance. We compared the number of subjective scale.s showing signi'icant differences between the drug
and placebo groups to the aumber of cognitive tasks showing significant group differences at each test
administration. We found that the pattern of differences between drug and placebo subjects is similar for
the subjective scales and the cognitive tasks. Fewer differences were observed on subjective scales and
cognitive tasks at administrations 1 and 4, when serum drug levels would have beer minimal, than at
administrations 2 and 3, when serum drug levels, and their effect on fatigur and performance, would have
been greater. Although this is not a rigorous statistical treatment, it reveals a similarity in the way subjective
indices of fatigue and cognitive measures of performance vary with test administration times.
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CONCLUSIONS
Amphetamine has been shown to abate subjective feelings of fatigue in this and other studies (8,32)
and to improve performance (8,13,26), however, this may not be sufficient to recommend its use in the fleet
at this time. Several important operational considerations remain unaiýawered. Additional research is
needed to determine: 1) whether stimulants are the best solution to the SUSOPs problem, 2) which
stimulant woual ". the best choice for use during SUSOPs, 3) the effect of amphetamine on flight
performance, 4) the most efficacious dose, 5) the optznum point in a mission to introduce the stimulant, 6)
the effect on sleep latency and impact on crew rest, and 7) what constitutes a practical but effective medical
screening program for aircrews in order to identify individuals who might have an adverse reaction to the
drug.
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APPENDIX A
This appendix contains a list of the statements presented during the administration of the Addiction
Research Center Inventory. The subject responded by circling each item that applied to them at the time.
For statements 1-12, a point was added to the total for each item that was circled. For statements 13-15, 1
point was added to the total for each item that was not circled. Scores could range from 0 (no fatigue) to 15
(maximum fatigue).
1 - My speech is slurred 1
2 - I am not as active as usual 1
3 - I have a feeling of just dragging along rather than coasting 1
4 - I feel sluggish 1
5 - My head feels heavy 1
6 - I feel like avoiding people although I usually do not feel this way1
7 - I feel dizzy 1
8 - It seems harder than usual to move around 1
9 - I am moody I
10 - People might say that I am a little dull right now 1
11 - I feel drowsy 1
12 - I am full of ener-, 2
13 - I can completely appreciate what others are saying when I am in this mood 2
14 - I feel more clear headed than dreamy 2
15 - A thrill has gone through me one or more times since I started answeriig these questions 2
1 Statement required a true response to contribute to fatigue score.
2 Statement required a false response to contribute to fatigue score.
A-1
APPENDIX B
This appendix contains a list of the statements presented during the administration of the Stanford
Sleepiness Scale. Subjects were instructed to circle the one statement that applied to them at the time. This
statement was their score. Scores could range from 1 (least sleepiness) to 7 (most sleepiness).
Scale Statements
Values
1 Feeling active and vital; alert; wide awake.
2 Functioning at a high level, but not at peak; able to concentrate.
3 Relaxed; awake; not at full alertness; responsive.
4 A little foggy; not at peak; let down.
5 Fogginess; beginning to lose interest in remaining awake; slowed down.
6 Sleepiness; prefer to be lying down; fighting sleep; woozy.
7 Almost in reverie; sleep onset soon; lost struggle to remain awake.
B-1
APPENDIX C
This appendix contains a list of adjectives presented during the Mood Questionnaire Subjects were
instructed to circle how strongly each adjective described their level of fatigue at that time by circling the
number "1," "2," or "3" corresponding to "not at all," "somewhat or slightly," or "mostly or generally,"
respectively. The total score was calcurated by adding the numbers circled. Scores could range from 5 (least
fatigued) to 15 (most fatigued).
Not at all Somewhat or slightly Mostly or generally
weary 1 2 3
lazy 1 2 3
drowsy 1 2 3
sluggish 1 2 3
inactive 1 2 3
I
c-i
